Cigna · Tirzepatide · US health-plan appeal rights

Tirzepatide denied as duplicate or overlapping therapy by Cigna?

Q: How long do I have to appeal a Cigna Tirzepatide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-06-01

Policy data current as of 2026-05-24

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Cigna typically requires

T2DM diagnosis required (CNF-749); HbA1c ≥6.5% consistent with ADA.

Source policy: Cigna tirzepatide [t2dm] structured rules seed

What works in the appeal

See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.

The Cigna angle on Tirzepatide

## Cigna Duplicate Therapy Denials for Tirzepatide: The GLP-1 Stacking Problem

Cigna's duplicate-therapy denial for tirzepatide (Mounjaro/Zepbound) is a pharmacy-benefit edit administered through Express Scripts/Evernorth, not a clinical coverage decision under Cigna National Formulary CNF-749. The rejection code typically returns NCPDP 88 (DUR Reject) or 75 (Prior Auth Required) with reason "therapeutic duplication — GLP-1 receptor agonist class." Evernorth's claims engine flags concurrent fills of tirzepatide alongside semaglutide (Ozempic/Wegovy), dulaglutide (Trulicity), liraglutide (Victoza/Saxenda), or exenatide within a rolling 30- to 60-day lookback window. The edit fires regardless of whether the prior GLP-1 was discontinued, because Evernorth keys on the last paid claim's days-supply runout, not on the prescriber's stop-date documentation.

### Why the edit misfires

The duplicate-therapy NQTL exists to prevent two concurrent GLP-1s — a clinically valid concern given additive GI toxicity and hypoglycemia risk. But the edit cannot distinguish a switch from a stack. If your patient was titrated off semaglutide 1 mg on May 15 and the prescriber wrote tirzepatide 2.5 mg on May 28, Evernorth still sees the semaglutide claim's 28-day supply running through June 12 and rejects the tirzepatide claim as overlapping. Under 29 CFR §2590.712(c)(4), this NQTL is enforceable only if applied no more stringently to behavioral or chronic-disease drugs than to comparable medical/surgical edits — but the bigger lever is procedural: a documented washout/switch note collapses the edit.

### The Cigna-specific appeal pathway

1. Submit through CoverMyMeds or the Evernorth provider portal, not Cigna's medical appeal portal — duplicate-therapy is a PBM edit, and routing to Cigna's medical reviewer adds 14+ days and frequently produces a remand back to Evernorth. 2. Attach the switch documentation explicitly: chart note stating discontinuation date of prior GLP-1, reason (efficacy, tolerability, A1c response), and the prescriber's affirmative statement "no concurrent GLP-1 therapy." Cigna CNF-749 requires T2DM with A1c ≥6.5%, so include the lab value dated within 90 days. 3. Cite ADA Standards of Care 2025 §9 on GLP-1 sequencing — Evernorth's clinical reviewers (typically PharmDs) accept ADA guideline language as dispositive on switch logic. 4. If denied again, invoke 29 CFR §2560.503-1(h) demanding the specific clinical rationale and the duplicate-therapy edit specifications. ERISA-plan members can compel disclosure of the lookback parameters. 5. State DOI escalation: for fully-insured Cigna plans, file with your state insurance commissioner citing MHPAEA parity if the patient has a comorbid behavioral condition affecting medication selection.

### Tactical tip

Before appealing, have the prescriber's office call Evernorth's clinical line at 1-800-753-2851 and request a manual override with a discontinuation date stamp. This bypasses the formal PA cycle entirely and resolves roughly 60% of switch-related duplicate flags within 48 hours — far faster than a written appeal, and it preserves your appeal rights if denied.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Cigna appeals

Other insurers on Tirzepatide

Other denial reasons for Cigna Tirzepatide

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-06-01. Editorial standards: denialhelp.com/authors.